KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted six newly-hired employees inducement options to purchase an aggregate of 96,750 shares of KalVista common stock on February 1, 2026 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stoc.

Business Wire • Feb 3, 2026

Wall Street Analysts Believe KalVista Pharmaceuticals (KALV) Could Rally 116.4%: Here's is How to Trade

The consensus price target hints at an 116.4% upside potential for KalVista Pharmaceuticals (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Feb 2, 2026

Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect?

The mean of analysts' price targets for KalVista Pharmaceuticals (KALV) points to an 118% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Jan 15, 2026

KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug

KalVista Pharmaceuticals Inc. (NASDAQ: KALV) on Thursday reported early commercial momentum for its hereditary angioedema treatment EKTERLY, highlighting growing prescriber adoption, repeat prescriptions and expanding global access following its mid-2025 launch.

Benzinga • Jan 9, 2026

KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided its preliminary fourth quarter and full year ended December 31, 2025 unaudited global net product revenue results and other operational indicators. “We are extremely pleased with our performance since launching EKTERLY in July, which reflects steady execution, growing utilization, and continued momentum across our business,” said Ben Palleiko, CEO of KalVista. “Fundamental dema.

Business Wire • Jan 8, 2026

KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. EKTERLY is the first and only oral on-demand treatment for HAE approved in Japan. EKT.

Business Wire • Dec 22, 2025

KalVista Pharmaceuticals, Inc. (KALV) Presents at Jefferies London Healthcare Conference 2025 Transcript

KalVista Pharmaceuticals, Inc. ( KALV ) Jefferies London Healthcare Conference 2025 November 19, 2025 8:30 AM EST Company Participants Benjamin Palleiko - CEO & Director Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Presentation Maurice Raycroft Jefferies LLC, Research Division Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies.

Seeking Alpha • Nov 24, 2025

KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript

KalVista Pharmaceuticals, Inc. ( KALV ) Q3 2025 Earnings Call November 11, 2025 8:30 AM EST Company Participants Ryan Baker - Head of Investor Relations Benjamin Palleiko - CEO & Director Paul Audhya - Chief Medical Officer Nicole Sweeny - Chief Commercial Officer Brian Piekos - Chief Financial Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Stacy Ku - TD Cowen, Research Division Matthew Ryan Tan - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to KalVista Pharmaceuticals' 2025 Third Quarter Financial Update and Operating Results Conference Call.

Seeking Alpha • Nov 11, 2025

KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and reported financial results for the third quarter ended September 30, 2025. “The US launch of EKTERLY is progressing with significant momentum, driven by strong early demand and rapid adoption among physicians and people living with HAE. We continue to see encouraging trends, with both new patient starts and repeat prescriptions increasing consistently,.

Business Wire • Nov 10, 2025

KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates

KalVista Pharmaceuticals, Inc. (KALV) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $0.91 per share a year ago.

Zacks Investment Research • Nov 11, 2025